|
Data extracted : 08/09/2010 |
| Formulary Section 5: Infections |
| Notes: |
Intravenous antibiotics are more expensive than oral equivalents and some are very expensive, they also put patients at risk of IV cannula infections. Oral antibiotics are usually fairly cheap. IM injections are rarely, if ever, indicated.
Course lengths: Prescriptions for oral antibiotics for in-patients should be reviewed at or before five days. Prescriptions for intravenous antibiotics should be reviewed at or before 48 hours, after which the patient should be considered for an oral antibiotic, if there is an equivalent available (see IV to oral switch policy). For uncomplicated urinary tract infections, three days treatment is usually sufficient in adult women. Complicated infections require longer treatment.
When initiating therapy with agents marked with , you must seek Microbiology/Infectious Diseases advice.
The restricted antimicrobials may be prescribed without discussion with microbiology if they are being used for an approved indication as specified. Use outside these indications (and any use for some antimicrobials) requires DOCUMENTED approval from one of the medical microbiologists or Infectious Diseases Physician prior to prescribing. |
|
| Details... |
| 05.01 Antibacterial drugs |
| 05.01.01 Penicillins |
| 05.01.01.01 Benzylpenicillin and phenoxymethylpenicillin |
Benzylpenicillin
(Crystapen®)
|
| Injection |
Phenoxymethylpenicillin
|
Tablet Oral Solution |
| 05.01.01.02 Penicillinase-resistant penicillins |
Flucloxacillin
|
Capsule Oral solution Injection
Note: CSM has advised that cholestatic jaundice may occur up to several weeks after treatment with Flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. LFT’s should be monitored where prolonged therapy is used. |
| 05.01.01.03 Broad-spectrum penicillins |
Amoxicillin
|
Capsule Oral suspension Injection
Note: If a 3g dose of amoxicillin is required, it is recommended that 6 x 500mg capsules be supplied, to be taken with plenty of fluid over a period of about half an hour. This is considerably less expensive than the use of Amoxil 3g sachets, and less unpleasant to take. |
Co-Amoxiclav
|
Tablet Soluble tablet Oral suspension Injection
Note: CSM has advised that cholestatic jaundice may occur either during or just after treatment with co-amoxiclav. It is more common in patients above the age of 65 years and in males. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.
For 625mg dose please prescribe as co-amoxiclav 375mg and amoxicillin 250mg as this is less expensive than the 625mg tablet.
|
| 05.01.01.04 Antipseudomonal penicillins |
Piperacillin and Tazobactam
(Tazocin ®)
|
Injection
Approved Clinical Indications:
Neutropenic sepsis in haematology patients
Pseudomonas infections (if Ceftazidime unsuitable)
Treatment of severe spontaneous bacterial peritonitis.
Late onset ventilator associated pneumonia |
| 05.01.01.05 Mecillinams |
| 05.01.02 Cephalosporins and other beta-lactams |
| 05.01.02 Cephalosporins |
Cefixime
(Suprax ®)
|
Tablet Paediatric Oral Suspension Restricted as per GUM / Gynae PID guidance only |
Cefotaxime
|
Injection
Approved Clinical Indications:
Neonates only |
Cefradine
|
Capsule Syrup |
Ceftazidime
|
Injection
Approved Clinical Indications:
Cystic fibrosis
Suspected/proven Pseudomonal infections (e.g. bronchiectasis with previous isolate)
Neutropaenic sepsis in oncology patients |
Ceftriaxone
|
Injection
Approved Clinical Indications:
Meningitis or intracranial sepsis
Pelvic Inflammatory Disease (stat dose for Gonococcal cover)
Acute epiglottitis
Home IV therapy for recurrent chest infections in paediatrics |
Cefuroxime
(Zinacef®)
|
| Injection |
| 05.01.02 Other beta-lactam antibiotics |
Aztreonam
(Azactam ®)
|
Injection
Approved Clinical Indications:
Cystic fibrosis |
Ertapenem
(Invanz ®)
|
Infusion
Approved Clinical Indications:
Approval by microbiology / ID only |
Meropenem
(Meronem ®)
|
Injection
Approved Clinical Indications:
Approval by Microbiology/ID only
As part of the haematology/paediatric oncology neutropenic sepsis protocol (only in patients who are at risk of seizures from imipenem eg moderate-severe renal impairment (CrCl <20ml/min), head injury, history of seizures).
Consultant approval for cystic fibrosis |
| 05.01.03 Tetracyclines |
Demeclocycline Hydrochloride
(Ledermycin®)
|
Capsule For use in SIADH only |
Doxycycline
|
Capsule Dispersible Tablet |
Lymecycline
(Tetralysal ® 300)
|
Capsule Restricted for use in dermatology |
Minocycline
|
Capsule Capsule MR For use in dermatology only |
Oxytetracycline
|
Tablet For use in dermatology or on microbiology advice.
|
| 05.01.03 Tigecycline |
Tigecycline
(Tygacil ®)
|
IV infusion
Approved Clinical Indications:
Microbiology/ID approval only for multiresistant acinetobacter and other multiresistant organisms where other options unavailable. |
| 05.01.04 Aminoglycosides |
Amikacin
|
Injection
Approved Clinical Indications:
Approval by Microbiology/ID only |
Gentamicin
|
Injection Intrathecal Injection (preservative free) |
Neomycin Sulphate
|
Tablet For use in bowel sterilisation |
Tobramycin
|
Injection
Approved Clinical Indications:
Cystic fibrosis
Adult bronchiectasis |
Tobramycin
(Tobi®)
|
| Nebuliser solution |
| 05.01.05 Macrolides |
Azithromycin
(Zithromax ®)
|
Capsule Oral suspension
Approved Clinical Indications:
Cystic fibrosis
Chlamydial infection
Prophylaxis for terminations of pregnancy |
Clarithromycin
|
Tablet Suspension
Approved Clinical Indications:
Intolerance to oral erythromycin
Paediatric CF patients
H.pylori eradication
Combination therapy for TB where there is intolerance / resistance to first line therapy.
For GU/ID use
|
Clarithromycin
|
Injection Change to oral erythromycin, not oral clarithromycin
Approved Clinical Indications:
If NBM / vomiting and a macrolide is indicated
Pelvic inflammatory desease (See Protocol)
Severe community aquired pneumonia (CAP)
For GU/ID use
|
Erythromycin
|
Tablet Oral suspension Injection - IV is restricted for use as a pro-kinetic |
| 05.01.06 Clindamycin |
Clindamycin
|
Capsule Liquid - Named patient use
Injection
IV Approved Clinical Indications:
Serious streptococcal soft tissue infections unresponsive to penicillins or patient is penicillin allergic
Bone and joint infections where the patient is penicillin allergic NB: Bioavailability of oral formulation is 90%
Pseudomembranous colitis is a serious toxic effect of clindamycin |
| 05.01.07 Some other antibacterials |
| 05.01.07 Chloramphenicol |
Chloramphenicol
|
Capsule Injection
Approved Clinical Indication:
Approval by Microbiology/ID only |
| 05.01.07 Fusidic acid |
Sodium fusidate
|
Tablet Suspension For use in Staphylococcus aureus infections, in combination with other agents. Normally use orally.
Infusion IV Approved Clinical Indication:
Approval by Microbiology/ID only (good oral bioavailability and IV route is irritant) NB: Fusidic acid should not be used as a single agent |
| 05.01.07 Vancomycin and teicoplanin |
Teicoplanin
(Targocid ®)
|
Injection
Approved Clinical Indication:
Allergy to vancomycin
Paediatric oncology
Endocarditis prophylaxis if penicillin allergic (see guideline)
Empirical therapy for sepsis associated with chronic granulomatous disease
Paediatric CF patients as per guidelines |
Vancomycin
|
Capsule Injection used orally Injection
NB: i) Injection as per microbiology guidelines ii) Oral preparation is restricted to use in pseudomembranous colitis as a second line agent. See guidelines on the treatment of C.difficile infection |
| 05.01.07 Linezolid |
Linezolid
|
Tablet Infusion
Approved Clinical Indications:
Approval by Microbiology/ID only
Consultant approval for cystic fibrosis
CSM advice: Full blood counts to be monitored weekly |
| 05.01.07 Polymyxins |
Colistin
(Colomycin®)
|
Tablet Syrup Injection
For bowel sterilisation. IV used for Pseudomonas
|
Colistin
(Promxin®)
|
Nebule
Nebulised solution for cystic fibrosis and neutropenic prophylaxis. Nebuliser used for Pseudomonas |
| 05.01.08 Sulphonamides and trimethoprim |
Co-trimoxazole
|
Tablet (Forte tablet is non formulary) Suspension Injection
Approved Clinical Indications:
Prophylaxis and treatment of PCP
Prophylaxis and treatment of spontaneous bacterial peritonitis |
Sulfadiazine
|
Tablet See BNF section 5.4.7 |
Trimethoprim
|
Tablet Suspension
This is the drug of choice for uncomplicated urinary tract infections in adults |
| 05.01.09 Antituberculous drugs |
Capreomycin
(Capastat ®)
|
Injection Restricted for use in resistant tuberculosis |
Cycloserine
|
Capsule Restricted for use in resistant tuberculosis
|
Ethambutol Hydrochloride
(Ethambutol®)
|
| Tablet |
Isoniazid
|
Tablet Elixir Injection |
Prothionamide
|
Capsule - Named patient use Restricted for use in resistant tuberculosis |
Pyrazinamide
|
| Tablet |
Rifabutin
(Mycobutin ®)
|
Capsule Restricted for us in mycobacterial disease |
Rifampicin
|
Capsule Syrup Infusion
Approved Clinical Indications:
Combination therapy in TB treatment
Post-exposure prophylaxis for Meningococcal and Haemophilus influenzae B meningitis.
Approval by Microbiology/ID NB: Rifampicin should not be used as a single agent (except in meningitis post-exposure prophylaxis above) |
Rifampicin and Isoniazid
(Rifinah® 300)
|
| Tablet |
Rifampicin and Isoniazid
(Rifinah® 150)
|
| Tablet |
Rifampicin and Isoniazid
(Rimactazid® 300)
|
| Tablet |
Rifampicin and Isoniazid and Pyrazinamide
(Rifater®)
|
| Tablet |
Streptomycin Sulphate
|
Injection Restricted for use in resistant tuberculosis |
| 05.01.10 Antileprotic drugs |
Dapsone
|
Tablet Restricted to dermatology use only or on microbiology approval or GU/ID use as 2nd line agent for Pneumocystis carnii pneumonia prophylaxis |
| 05.01.11 Metronidazole and tinidazole |
Metronidazole
|
Tablet Suspension Infusion Suppository |
Tinidazole
(Fasigyn ®)
|
Tablet Restricted as per GU guidelines |
| 05.01.12 Quinolones |
| CSM Warning – quinolones may induce convulsions in patients with or without a history of convulsions; taking NSAID’s at the same time may also induce them. 4-quinolones may also induce tendon damage. (At the first sign of pain or inflammation treatment should be discontinued). |
Ciprofloxacin
|
Tablet Suspension Infusion
IV Approved Clinical Indication:
Approval by Microbiology/ID only
Bioavailability of the oral formulation is equivalent to IV (therefore oral route should be used unless genuinely NBM) City campus: As per oncology neutropenic sepsis protocol if penicillin allergic and unable to take oral medication |
Levofloxacin
(Tavanic®)
|
| Tablet |
Moxifloxacin
(Avelox ®)
|
Tablet
Approved Clinical Indication:
For multi-resistant TB or where other first line TB treatments are inappropriate |
Ofloxacin
|
Tablet Restricted for treatment of pelvic inflammatory disease only |
| 05.01.13 Urinary-tract infections |
Cefradine
|
| See section 5.1.2 |
Nitrofurantoin
|
Tablet Oral suspension
NB: Avoid in renal impairment |
Trimethoprim
|
| See section 5.1.8 |
| 05.02 Antifungal drugs |
| 05.02 Drugs used in fungal infections |
Amphotericin
(Abelcet ®)
|
Infusion
Approve Clinical Indications:
Consultant approval for haematology patients
Critical care at city campus as per guidelines |
Amphotericin
(AmBisome ®)
|
Infusion
Approve Clinical Indications:
Consultant approval for haematology patients
Paediatric oncology
|
Amphotericin
(Fungilin®)
|
| See section 12.3.2 |
Amphotericin
(Fungizone ®)
|
Infusion
Approve Clinical Indications:
For intravitreal use, intrathecal and for eye/ear drop preparation only |
Caspofungin
(Cancidas ®)
|
Infusion
Approve Clinical Indications:
Consultant approval for haematology patients |
Fluconazole
|
Capsule Oral suspension Infusion
IV Approved Clinical Indication:
Haematology/oncology protocol if NBM or poorly absorbing.
Bioavailability of the oral formulation is > 90% (therefore oral route should be used unless genuinely NBM) |
Flucytosine
(Ancotil ®)
|
Infusion Restricted for proven systemic yeast infections. Discuss with microbiologist - Serum assays required to minimise toxicity. |
Griseofulvin
|
Tablet Restricted for scalp and dermatophyle infections in children |
Itraconazole
(Sporanox®)
|
Capsule Liquid |
Miconazole
(Daktarin®)
|
| See section 12.3.2 |
Nystatin
(Nystan®)
|
| See section 12.3.2 |
Terbinafine
|
Tablet Restricted for use in severe tinea infections where oral therapy is appropriate |
Voriconazole
(Vfend ®)
|
Tablet Suspension Infusion
Approve Clinical Indications:
consultant approval for haematology / bone marrow transplant patients
ID use for HIV patients |
| 05.03 Antiviral drugs |
| 05.03.01 HIV infection |
| 05.03.01 Nucleoside reverse transcriptase inhibitors |
Abacavir
(Ziagen ®)
|
Tablet Oral Solution Restricted to ID / GU Medicine advice only |
Abacavir and Lamivudine
(Kivexa ®)
|
Tablet Restricted to ID / GU Medicine advice only |
Abacavir and Lamivudine and Zidovudine
(Trizivir ®)
|
Tablet Restricted to ID / GU Medicine advice only |
Didanosine
(Videx ®)
|
Tablet Capsule EC Powder to make suspension is named patient Restricted to ID / GU Medicine advice only |
Emtricitabine
(Emtriva ®)
|
Capsule Oral Solution Restricted to ID / GU Medicine advice only |
Lamivudine
(Epivir ®)
|
Tablet Oral Solution For HIV infection in combination with other antiretroviral drugs Restricted to ID / GU Medicine advice only |
Lamivudine
(Zeffix ®)
|
Tablet Oral Solution For chronic hepatitis B infection Restricted to ID / GU Medicine advice only |
Stavudine
(Zerit ®)
|
Capsule Oral Solution Restricted to ID / GU Medicine advice only |
Tenofovir and Emtricitabine
(Truvada ®)
|
Tablet Restricted to ID / GU Medicine advice only |
Tenofovir Disproxil
(Viread ®)
|
Tablet Restricted to ID / GU Medicine advice only |
Zidovudine
(Retrovir ®)
|
Capsule Oral solution Injection Restricted to ID / GU Medicine and Microbiology advice only |
Zidovudine and Lamivudine
(Combivir ®)
|
Tablet Restricted to ID / GU Medicine advice only |
Zidovudine and lamivudine
(Combivir ®)
|
Tablet Restricted to ID / GU Medicine advice only |
| 05.03.01 Protease inhibitors |
Amprenavir
(Agenerase ®)
|
Capsule Oral Solution Restricted to ID / GU Medicine advice only |
Atazanavir
(Reyataz ®)
|
Capsule Restricted to ID / GU Medicine advice only |
Fosamprenavir
(Telzir ®)
|
Tablet Oral Suspension Restricted to ID / GU Medicine advice only |
Indinavir
(Crixivan ®)
|
Capsule Restricted to ID / GU Medicine advice only |
Lopinavir and Ritonavir
(Kaletra ®)
|
Capsule Tablet Liquid Restricted to ID / GU Medicine advice only |
Ritonavir
(Norvir ®)
|
Capsule Oral Solution Restricted to ID / GU Medicine advice only |
Saquinavir
(Invirase ®)
|
Capsule Tablet Restricted to ID / GU Medicine advice only |
Tipranavir
(Aptivus ®)
|
Capsule Restricted to ID / GU Medicine advice only |
| 05.03.01 Non-nucleoside reverse transcriptase inhibitors |
Efavirenz
(Sustiva ®)
|
Capsule Tablet Oral Solution Restricted to ID / GU Medicine advice only |
Nevirapine
(Viramune ®)
|
Tablet Suspension Restricted to ID / GU Medicine advice only |
| 05.03.01 Other antiretrovirals |
Enfuvirtide
(Fuzeon ®)
|
Injection Restricted to ID / GU Medicine advice only |
| 05.03.02 Herpesvirus infections |
| 05.03.02.01 Herpes simplex and varicella-zoster infection |
In immunocompromised patient for treatment or prophylaxis – please refer to specialist protocol or seek expert advice. In pregnancy please seek specialist advice. |
Aciclovir
|
Tablet Suspension Injection
For Herpes Simplex and Varicella Zoster. For Herpes infection in children. IV - For Herpes Encephalitis, Herpes Zoster and Simplex in the immunocompromised |
Valaciclovir
(Valtrex ®)
|
Tablet
Approved Clinical Indications:
Haematology patients
Herpes Zoster
GU/ID consultant advice only |
| 05.03.02.02 Cytomegalovirus infrection |
Cidofovir
(Vistide®)
|
| Infusion |
Foscarnet Sodium
(Foscavir ®)
|
Infusion
Approved Clinical Indications:
Consultant approval for haematology patients only
Approval by Microbiology/ID in all other cases |
Ganciclovir
(Cymevene ®)
|
Infusion
Approved Clinical Indications:
Consultant approval for haematology patients ONLY
Approval by Microbiology/ID in all other cases |
Valganciclovir
(Valcyte ®)
|
Tablet
Approved Clinical Indications:
Consultant approval for haematology patients
Renal transplant patients as per guidelines for prophylaxis |
| 05.03.03 Viral hepatitis |
Adefovir Dipivoxil
(Hepsera®)
|
Tablet Also used for Lamivudine resistant hepatitis B |
| 05.03.04 Influenza |
Amantadine Hydrochloride
(Lysovir ®)
|
Capsule Infusion is named patient use For use in early management / prevention of influenza A and parkinson’s disease
Infusion is restricted for chronic pain |
Oseltamivir
(Tamiflu ®)
|
Capsule Suspension Restricted for treatment of infulenza as per NICE guidance. Microbiology / virology only. |
| 05.03.05 Respiratory syncytial virus |
Palivizumab
(Synagis ®)
|
Injection Restricted for respiratory syncytial virus (RSV) in paediatrics |
Ribavirin
|
Capsule Tablet Injection is named patient use
This drug is reserved for use in severe respiratory syncytial virus (RSV) bronchiolitis in infants, children and immunocompromised patients. For hepatitis C infection |
Ribavirin
(Virazole ®)
|
Inhalation This drug is reserved for use in severe respiratory syncytial virus (RSV) bronchiolitis in infants, children and immunocompromised patients. For hepatitis C infection
Approved Clinical Indications:
Approval by microbiology / ID only
|
| 05.04 Antiprotozoal drugs |
| 05.04.01 Antimalarials |
| 05.04.01 Chloroquine |
Chloroquine
|
Tablet Syrup (Injection is non formulary) |
| 05.04.01 Mefloquine |
Mefloquine
(Lariam®)
|
| Tablet |
| 05.04.01 Primaquine |
Primaquine
|
| Tablet - Named patient use |
| 05.04.01 Proguanil |
Proguanil Hydrochloride
(Paludrine®)
|
| Tablet |
Proguanil Hydrochloride with Atovaquone
(Malarone®)
|
| Tablet |
| 05.04.01 Pyrimethamine |
Pyrimethamine and Dapsone
|
Tablet Restricted for ID or haematology use |
Pyrimethamine with Sulfadoxine
(Fansidar®)
|
| Tablet |
| 05.04.01 Quinine |
Quinine Dihydrochloride
|
| Injection |
Quinine Sulphate
|
| Tablet |
| 05.04.02 Amoebicides |
Diloxanide Furoate
(Diloxanide®)
|
| Tablet |
Metronidazole
|
| See section 5.1.11 |
| 05.04.03 Trichomonacides |
Metronidazole
|
| See Section 5.1.11 |
| 05.04.04 Antigiardial drugs |
Mepacrine Hydrochloride
|
| Tablet is named patient use |
Metronidazole
|
| See Section 5.1.11 |
| 05.04.05 Leishmaniacides |
| 05.04.06 Trypanocides |
| 05.04.07 Drugs for toxoplasmosis |
Sulfadiazine
|
| See Section 5.1.8 |
| 05.04.08 Drugs for pneumocystis pneumonia |
Atovaquone
(Wellvone®)
|
Suspension Used if patient is intolerant of co-trimoxazole |
Co-trimoxazole
|
| See Section 5.1.8 |
Pentamidine Isetionate
(Pantacarinat®)
|
Injection Nebules |
| 05.05 Anthelmintics |
| 05.05.01 Drugs for threadworms |
Albendazole
|
| Tablet is named patient use |
Mebendazole
|
Tablet Suspension |
| 05.05.02 Ascaricides |
| 05.05.03 Drugs for tapeworm infections |
| 05.05.04 Drugs for hookworms |
| 05.05.05 Schistosomicides |
| 05.05.06 Filaricides |
| 05.05.07 Drugs for cutaneous larva migrans |
| 05.05.08 Drugs for strongyloidiasis |
| .... |
| Non Formulary Items |
| 05.03.04 - Amantadine Hydrochloride
(Symmetrel®)
|
| 05.01.04 - Amikacin
(Amikin®)
|
| 05.02 - Amphotericin
(Amphocil®)
|
| 05.01.01.03 - Ampicillin
|
| 05.01.01.03 - Ampicillin
(Penbritin®)
|
| 05.04.01 - Artemether with lumefantrine
(Riamet®)
|
| 05.04.08 - Atovaquone
(With Proguanil Hydrochloride)
|
| 05.01.02 - Cefaclor
|
| 05.01.02 - Cefaclor
(Distaclor®)
|
| 05.01.02 - Cefaclor
(Distaclor® MR)
|
| 05.01.02 - Cefadroxil
|
| 05.01.02 - Cefadroxil
(Baxan®)
|
| 05.01.02 - Cefalexin
|
| 05.01.02 - Cefalexin
(Ceporex®)
|
| 05.01.02 - Cefalexin
(Keflex®)
|
| 05.01.02 - Cefpodoxime
(Orelox®)
|
| 05.01.02 - Cefuroxime Axetil
|
| 05.04.01 - Chloroquine
(Malarivon®)
|
| 05.04.01 - Chloroquine
(Paludrine® Avloclor)
|
| 05.01.05 - Clarithromycin
(Clarosip®)
|
| 05.01.05 - Clarithromycin
(Klaricid® XL)
|
| 05.01.10 - Clofazimine
|
| 05.01.01.03 - Co-Fluampicil
|
| 05.01.01.03 - Co-Fluampicil
(Magnapen®)
|
| 05.01.07 - Daptomycin
|
| 05.01.07 - Daptomycin
(Cubicin®)
|
| 05.04.01 - Doxycycline
|
| 05.01.03 - Doxycycline
(Vibramycin-D®)
|
| 05.03.03 - Entecavir
(Baraclude®)
|
| 05.01.05 - Erythromycin
(Erymax®)
|
| 05.01.05 - Erythromycin
(Erythrocin®)
|
| 05.01.05 - Erythromycin
(Erythromycin Ethyl Succinate)
|
| 05.01.05 - Erythromycin
(Erythromycin Lactobionate)
|
| 05.01.05 - Erythromycin
(Erythroped® A)
|
| 05.03.02.01 - Famciclovir
(Famvir®)
|
| 05.01.04 - Gentamicin
(Cidomycin®)
|
| 05.01.04 - Gentamicin
(Genticin®)
|
| 05.01.04 - Gentamicin
(Isotonic Gentamicin Injection)
|
| 05.01.02 - Imipenem with Cilastatin
(Primaxin®)
|
| 05.01.02 - Imipenem with Cilastatin (IM Injection)
(Primaxim®)
|
| 05.03.02.01 - Inosine Pranobex
(Imunovir®)
|
| 05.02 - Ketoconazole
(Nizoral®)
|
| 05.01.13 - Methenamine Hippurate
(Hiprex®)
|
| 05.01.11 - Metronidazole
(Flagyl® S)
|
| 05.01.11 - Metronidazole
(Metrolyl®)
|
| 05.01.03 - Minocycline
(Acnamino® MR)
|
| 05.01.03 - Minocycline
(Minocin® MR)
|
| 05.01.03 - Minocycline
(Sebomin® MR)
|
| 05.01.12 - Nalidixic Acid
(Uriben®)
|
| 05.03.01 - Nelfinavir
(Viracept®)
|
| 05.01.04 - Netilmicin
(Netillin®)
|
| 05.01.13 - Nitrofurantoin
(Furadantin®)
|
| 05.01.13 - Nitrofurantoin
(Macrobid®)
|
| 05.01.12 - Norfloxacin
|
| 05.01.12 - Norfloxacin
(Utinor®)
|
| 05.05.01 - Piperazine
(Piperazine® Citrate)
|
| 05.05.01 - Piperazine
(with Sennosides)
|
| 05.01.01.05 - Pivmecillinam Hydrochloride
(Selexid®)
|
| 05.02 - Posaconazole
(Noxafil®)
|
| 05.04.01 - Proguanil Hydrochloride
(With Chloroquine)
|
| 05.04.01 - Proguanil Hydrochloride with Atovaquone
(Malarone® Raediatric)
|
| 05.04.01 - Pyrimethamine
(Darprim®)
|
| 05.01.07 - Quinupristin and dalfopristin
(Synercid®)
|
| 05.03.05 - Ribavirin
(Copegus®)
|
| 05.03.05 - Ribavirin
(Rebetol®)
|
| 05.01.09 - Rifampicin
(Rifadin®)
|
| 05.01.09 - Rifampicin
(Rimactane®)
|
| 05.04.05 - Sodium Stibogluconate
(Pentostam®)
|
| 05.01.05 - telithromycin
(Ketek®)
|
| 05.01.01.02 - Temocillin
(Negaban®)
|
| 05.01.03 - Tetracycline
|
| 05.01.03 - Tetracycline
(Deteclo®)
|
| 05.01.01.04 - Ticarcillin
(Timentin®)
|
| 05.04.02 - Tinidazole
|
| 05.03.04 - Zanamivir
(Relenza®)
|
| |